Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke

Stroke

Volumn 31, Issue 1, 2000, Pages 26-32

  Johansson, Lars ^a   Jansson, Jan Håkan ^b   Boman, Kurt ^b   Nilsson, Torbjörn K ^b   Stegmayr, Birgitta ^b   Hallmans, Göran ^b  

^a Skelleftea Hospital   (Sweden)

^b NONE

Author keywords

Cerebral hemorrhage; Cerebral infarction; Fibrinolysis; Risk factors

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; STROKE;

EID: 0033982804     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.31.1.26     Document Type: Article

References (42)

1. Peltonen M, Huhtasaari F, Stegmayr B, Lundberg V, Asplund K. Secular trends in social patterning of cardiovascular risk factor levels in Sweden: the Northern Sweden MONICA Study, 1986-1994: Multinational Monitoring of Trends and Determinants in Cardiovascular Disease. J Intern Med. 1998;244:1-9.
2. Stegmayr B, Asplund K, Kuulasmaa K, Rajakangas AM, Thorvaldsen P, Tuomilehto J. Stroke incidence and mortality correlated to stroke risk factors in the WHO MONICA Project: an ecological study of 18 populations. Stroke. 1997;28:1367-1374.
3. Heller RF, Chinn S, Pedoe HD, Rose G. How well can we predict coronary heart disease? Findings in the United Kingdom Heart Disease Prevention Project. BMJ (Clin Res Ed). 1984;288:1409-1411.
4. Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile: a statement for health professionals. Circulation. 1991;83: 356-362.
5. Hamsten A. The hemostatic system and coronary heart disease. Thromb Res. 1993;70:1-38.
6. Lijnen HR, Collen D. Impaired fibrinolysis and the risk for coronary heart disease. Circulation. 1996;94:2052-2054.
7. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet. 1993;342:1076-1079.
8. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC, for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med. 1995;332:635-641.
9. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet. 1993;341:1165-1168.
10. Jansson JH, Olofsson BO, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease: a 7-year follow-up. Circulation. 1993;88: 2030-2034.
11. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987;2:3-9.
12. Jansson JH, Nilsson TK, Olofsson BO. Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. Eur Heart J. 1991;12:157-161.
13. Juhan-Vague I, Pyke SD, Alessi MC, Jespersen J, Haverkate F, Thompson SG, on behalf of the ECAT Study Group (European Concerted Action on Thrombosis and Disabilities). Fibrinolylic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation. 1996;94:2057-2063.
14. Lindgren A, Lindoff C, Norrving B, Astedt B, Johansson BB. Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients. Stroke. 1996;27:1066-1071.
15. Macko RF, Kittner SJ, Epstein A, Cox DK, Wozniak MA, Wityk RJ, Stern BJ, Sloan MA, Sherwin R, Price TR, McCarter RJ, Johnson CJ, Earley CJ, Buchholz DW, Stolley PD. Elevated tissue plasminogen activator antigen and stroke risk: the Stroke Prevention In Young Women Study. Stroke. 1999;30:7-11.
16. Margaglione M, Di Minno G, Grandone E, Vecchione G, Celentano E, Cappucci G, Grilli M, Simone P, Panico S, Mancini M. Abnormally high circulation levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with a history of ischemic stroke. Arterioscler Thromb. 1994;14:1741-1745.
17. Kristensen B, Malm J, Nilsson TK, Hultdin J, Carlberg B, Olsson T. Increased fibrinogen levels and acquired hypofibrinolysis in young adults with ischemic stroke. Stroke. 1998;29:2261-2267.
18. Carter AM, Catto AJ, Grant PJ. Determinants of tPA antigen and associations with coronary artery disease and acute cerebrovascular disease. Thromb Haemost. 1998;80:632-636.
19. Ridker PM, Hennekens CH, Stampfer MJ, Manson JE, Vaughan DE. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet. 1994;343:940-943.
20. Smith FB, Lee AJ, Fowkes FG, Price JF, Rumley A, Lowe GD. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol. 1997;17: 3321-3325.
21. Salomaa V, Stinson V, Kark JD, Folsom AR, Davis CE, Wu KK. Association of fibrinolytic parameters with early atherosclerosis: the ARIC Study. Circulation. 1995;91:284-290.
22. Killewich LA, Gardner AW, Macko RF, Hanna DJ, Goldberg AP, Cox DK, Flinn WR. Progressive intermittent claudication is associated with impaired fibrinolysis. J Vasc Surg. 1998;27:645-650.
23. Blann AD, Dobrotova M, Kubisz P, McCollum CN, von Willebrand factor, soluble P-selectin, tissue plasminogen activator and plasminogen activator inhibitor in atherosclerosis. Thromb Haemost. 1995;74: 626-630.
24. Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood. 1991;78:3114-3124.
25. Rånby M, Nguyen G, Scarabin PY, Samama M. Immunoreactivity of tissue plasminogen activator and of its inhibitor complexes: biochemical and multicenter validation of a two site immunosorbent assay. Thromb Haemost. 1989;61:409-414.
26. Bergsdorf N, Johansson E, Norrman B, TintElize tPA-PAI-1, a new method for the measurement of tPA-PAI-1 complexes. Fibrinol Proteol. 1998;12(suppl 1):49. Abstract No. 139.
27. Brännström I. Community Participation and Social Patterning in Cardiovascular Disease Intervention [dissertation]. Umeå, Sweden: Department of Epidemiology and Public Health, Umeå University; 1993.
28. Weinehall L, Johnson O, Jansson JH, Boman K, Huhtasaari F, Hallmans G, Dahlen GH, Wall S. Perceived health modifies the effect of biomedical risk factors in the prediction of acute myocardial infarction: an incident case-control study from northern Sweden. J Intern Med. 1998;243:99-107.
29. WHO MONICA Project Principal Investigators (prepared by Tunstall-Pedoe H). The World Health Organization MONICA Project (Monitoring Trends and Determinants in Cardiovascular Disease): a major international collaboration. J Clin Epidemiol. 1988;41:105-114.
30. Stegmayr B, Asplund K. Measuring stroke in the population: quality of routine statistics in comparison with a population-based stroke registry. Neuroepidemiology. 1992;11:204-213.
31. Rånby M, Bergsdorf N, Nilsson T, Mellbring G, Winhlad B, Bucht G. Age dependence of tissue plasminogen activator concentrations in plasma, as studied by an improved enzyme-linked immunosorbent assay. Clin Chem. 1986;32:2160-2165.
32. Eliasson M, Jansson JH, Nilsson P, Asplund K. Increased levels of tissue plasminogen activator antigen in essential hypertension: a population-based study in Sweden. J Hypertens. 1997;15:349-356.
33. Sundell IB, Nilsson TK, Rånby M, Hallmans G, Hellsten G. Fibrinolytic variables are related to age, sex, blood pressure, and body build measurements: a cross-sectional study in Norsjö, Sweden. J Clin Epidemiol. 1989;42:719-723.
34. Juhan-Vague I, Alessi MC, Vague P. Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus. Ann Med. 1996;28:371-380.
35. van der Bom JG, de Knijff P, Haverkate F, Bots ML, Meijer P, de Jong PT, Hofman A, Kluft C, Grobbee DE. Tissue plasminogen activator and risk of myocardial infarction: the Rotterdam Study. Circulation. 1997; 95:2623-2627.
36. Steeds R, Adams M, Smith P, Channer K, Samani NJ. Distribution of tissue plasminogen activator insertion/deletion polymorphism in myocardial infarction and control subjects. Thromb Haemost. 1998;79:980-984.
37. Eriksson P, Kallin B, van't Hooft FM, Båvenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A. 1995;92:1851-1855.
38. Catto AJ, Carter AM, Stickland M, Bamford JM, Davies JA, Grant PJ. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphism and levels in subjects with cerebrovascular disease. Thromb Haemost. 1997;77:730-734.
39. Nilsson T, Wallen P, Mellbring G. In vivo metabolism of human tissue-type plasminogen activator. Scand J Haematol. 1984;33:49-53.
40. Alessi MC, Juhan-Vague I, Declerck PJ, Anfosso F, Gueunoun E, Collen D. Correlations between t-PA and PAI-1 antigen and activity and t-PA/PAI-1 complexes in plasma of control subjects and of patients with increased t-PA or PAI-1 levels. Thromb Res. 1990;60:509-516.
41. Nordenhem A, Wiman B. Tissue plasminogen activator (tPA) antigen in plasma: correlation with different tPA/inhibitor complexes. Scand J clin Lab Invest. 1998;58:475-483.
42. Chandler WL, Alessi MC, Aillaud MF, Henderson P, Vague P, Juhan-Vague I. Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex: relationship to elevated TPA antigen in patients with high PAI-1 activity levels. Circulation. 1997;96:761-768.